In their mechanisms of inhibition (MOIs), JAKi are widely used to treat arthritis because they block JAK/STAT signaling and reduce the downstream production of inflammatory cytokines and limit the activation of synovial fibroblasts, which are key effectors of persistent joint inflammation (66) (Table 1). This evidence concerns the gene SOAT1 and arthritic joint disease.